Oct 25, 2013 7:00am EDT Can-Fite BioPharma Successfully Concludes $6,000,000 Public Offering With an Over-Subscription of 300%
Oct 22, 2013 3:10pm EDT Can-Fite BioPharma Announces Clinical and Corporate Developments for Near-Term Events
Oct 15, 2013 7:00am EDT Can-Fite BioPharma's CF101 Drug Selected as one of the "Top Autoimmune/Anti-Inflammatory Disease Projects to Watch" by Elsevier Business Intelligence
Oct 10, 2013 7:00am EDT Can-Fite BioPharma to Present Its Liver Cancer Drug at the 18th World Congress on Advances in Oncology in Greece
Oct 02, 2013 7:00am EDT Can-Fite's Subsidiary OphthaliX to Present at Ophthalmology Futures European Forum
Sep 03, 2013 1:38pm EDT Can-Fite to Present at Rodman & Renshaw Global Investment Conference on September 9, 2013
Aug 28, 2013 11:12am EDT Can-Fite to Initiate a Phase II Study With CF102 in 130 Patients With Advanced Liver Cancer
